Compare commits

...

3 commits

Author SHA1 Message Date
Teleo Agents
e4ddbac207 extract: 2024-11-01-aspe-medicare-anti-obesity-medication-coverage
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
2026-03-16 11:31:42 +00:00
Leo
4576cbbe76 Merge pull request 'extract: 2024-11-21-futardio-proposal-proposal-13' (#1023) from extract/2024-11-21-futardio-proposal-proposal-13 into main 2026-03-16 11:28:35 +00:00
Teleo Agents
70b0bfdcbd extract: 2024-11-21-futardio-proposal-proposal-13
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
2026-03-16 11:27:31 +00:00
3 changed files with 32 additions and 2 deletions

View file

@ -39,6 +39,12 @@ The GLP-1 case is particularly stark because the clinical evidence is robust (ca
The claim that budget scoring "systematically" undervalues prevention requires evidence beyond a single case. However, the GLP-1 divergence is consistent with known CBO methodology (10-year window, conservative assumptions) and parallels similar scoring challenges for other preventive interventions (vaccines, screening programs). The structural bias is well-documented in health policy literature, though this source provides the most dramatic single-case illustration.
### Additional Evidence (confirm)
*Source: [[2024-11-01-aspe-medicare-anti-obesity-medication-coverage]] | Added: 2026-03-16*
The CBO vs. ASPE divergence on Medicare GLP-1 coverage provides concrete evidence: CBO projects $35B in additional spending (2026-2034) using budget scoring methodology, while ASPE projects net savings of $715M over 10 years using clinical economics methodology that includes downstream event avoidance. The $35.7B gap between these estimates demonstrates how budget scoring rules structurally disadvantage preventive interventions. CBO uses conservative uptake assumptions and doesn't fully count avoided hospitalizations and disease progression within the 10-year window, while ASPE includes 38,950 CV events avoided and 6,180 deaths avoided. Both are technically correct but answer different questions—budget impact vs. clinical economics.
---
Relevant Notes:

View file

@ -7,9 +7,13 @@ date: 2024-11-01
domain: health
secondary_domains: [internet-finance]
format: policy
status: unprocessed
status: enrichment
priority: medium
tags: [glp-1, medicare, obesity, budget-impact, CBO, federal-spending]
processed_by: vida
processed_date: 2026-03-16
enrichments_applied: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings.md"]
extraction_model: "anthropic/claude-sonnet-4.5"
---
## Content
@ -45,3 +49,12 @@ WHY ARCHIVED: The CBO vs. ASPE divergence reveals a systematic bias in how preve
EXTRACTION HINT: Focus on the methodological divergence as evidence of structural misalignment in policy evaluation, not just the GLP-1 budget numbers
flagged_for_leo: ["Budget scoring methodology systematically disadvantages prevention — this is a cross-domain structural problem affecting all preventive health investments"]
## Key Facts
- CBO estimates Medicare coverage of anti-obesity medications would increase federal spending by $35 billion over 2026-2034
- ASPE estimates net savings of $715 million over 10 years from Medicare GLP-1 coverage (range: $412M to $1.04B)
- Broad semaglutide access projected to avoid 38,950 CV events and 6,180 deaths over 10 years
- Annual Part D cost increase from Medicare GLP-1 coverage: $3.1-6.1 billion
- Approximately 10% of Medicare beneficiaries would be eligible under proposed criteria requiring comorbidities
- Proposed eligibility criteria require CVD history, heart failure, CKD, or prediabetes—not just BMI threshold

View file

@ -6,9 +6,13 @@ url: "https://www.futard.io/proposal/ApywwMrE9vkWiatZwQVU6wdvNsHrYZkhegNCV5XDZ8y
date: 2024-11-21
domain: internet-finance
format: data
status: unprocessed
status: null-result
tags: [futardio, metadao, futarchy, solana, governance]
event_type: proposal
processed_by: rio
processed_date: 2026-03-16
extraction_model: "anthropic/claude-sonnet-4.5"
extraction_notes: "LLM returned 0 claims, 0 rejected by validator"
---
## Proposal Details
@ -27,3 +31,10 @@ event_type: proposal
- Autocrat version: 0.3
- Completed: 2024-11-25
- Ended: 2024-11-25
## Key Facts
- MetaDAO Proposal #13 was created on 2024-11-21 and failed on 2024-11-25
- Proposal used Autocrat version 0.3
- Proposal duration was 4 days
- Proposal account: ApywwMrE9vkWiatZwQVU6wdvNsHrYZkhegNCV5XDZ8yV